Fig. 2 | Scientific Reports

Fig. 2

From: Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens

Fig. 2

Robust T-cell responses but attenuated antibody and B-cell responses following adenoviral vector priming. Immune responses were analyzed at 28 days after primary vaccination with BNT162b2, mRNA-1273, and ChAdOx1. Subjects with ≥ 40 years of age were analyzed. (A) Serum anti-spike titers were measured with ECLIA. (B) Neutralization titers against authentic SARS-CoV-2 virus were measured. (C) Frequencies of CD19 + CD20 + IgG + B cells which bind SARS-CoV-2 spike RBD were measured with flow cytometry. (D) Frequencies of spike-specific CD4 and CD8 T cells were measured using AIM assay. (E) Indicated humoral immune parameters were normalized to spike+ CD4 T cell frequencies. (F) Indicated humoral immune parameters were normalized to spike+ CD8 T cell frequencies. Data were analyzed by Kruskal-Wallis test and subsequent Dunn’s multiple comparison test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).

Back to article page